Investing.com - Bicycle Therapeutics (NASDAQ:BCYC) reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Bicycle Therapeutics announced earnings per share of $-0.9 on revenue of $4.38M. Analysts polled by Investing.com anticipated EPS of $-0.8408 on revenue of $3.69M.
Bicycle Therapeutics shares are down 5.03% from the beginning of the year, still down 60.34% from its 52 week high of $62.08 set on November 15, 2021. They are outperforming the Nasdaq which is down 19.07% from the start of the year.
Bicycle Therapeutics shares gained 7.91% in intra-day trade following the report.
Bicycle Therapeutics follows other major Healthcare sector earnings this month
Bicycle Therapeutics's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar